Mvasi Is First Biosimilar Drug Approved for Cancer

THURSDAY, Sept. 14, 2017 -- The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was found to be biosimilar to the anti-cancer drug Avastin, the FDA said Thursday in a news...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news